51
Views
0
CrossRef citations to date
0
Altmetric
Drug Evaluation

Methylphenidate transdermal system for the treatment of attention-deficit/hyperactivity disorder

Pages 613-620 | Published online: 25 Oct 2007
 

Abstract

The methylphenidate transdermal system (MTS) is the only nonoral medication approved by the US FDA for treating the symptoms of attention-deficit/hyperactivity disorder (ADHD). MTS patches deliver methylphenidate through the skin directly into the bloodstream, largely circumventing the first-pass metabolism of the GI tract and liver that occurs with orally administered methylphenidate. Clinical studies in school-aged children have shown MTS to be well tolerated and effective in the treatment of ADHD. Adverse effects most commonly seen in clinical studies are consistent with those seen with the use of other methylphenidate products and include decreased appetite, insomnia, headache, nausea, vomiting, anorexia and weight loss. When worn for the recommended 9 h, MTS demonstrated significant reductions in the core symptoms of ADHD from 2 through 12 h post-application.

Financial disclosure & competing interests

Thomas Rugino, MD has participated as a medical consultant and has participated in speakers‘ bureau programs for Cephalon, Inc. (PA, USA), Novartis Pharmaceuticals (UK), Shire Pharmaceuticals (PA, USA) and UCB Pharma (NY, USA). He has also participated as a medical consultant for Lexicor Medical Technology LLC (FL, USA). Children‘s Specialized Hospital has received research grant funding from Cephalon, Inc, Novartis Pharmaceuticals, Shire Pharmaceuticals, UCB Pharma, Sanofi-Aventis and Bristol-Myers Squibb Pharmaceutical Research Institute, Inc.

The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Acknowledgements

The author would like to thank Shire Pharmaceuticals and Amy M Horton for providing clinical trial information and assistance in the preparation of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.